Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNuformix Regulatory News (NFX)

Share Price Information for Nuformix (NFX)

Share Price is delayed by 15 minutes
Get Live Data
0.165    0.00 (0.00%)
Bid:
0.16
Ask:
0.17
Spread: 0.01 (6.25%)
Market Cap: £4.31m
NFX Live PriceLast checked at - London Stock Exchange

Intraday Nuformix Share Chart

Result of AGM

20 Aug 2020 11:33

RNS Number : 7285W
Nuformix PLC
20 August 2020
 

Nuformix plc

("Nuformix" or the "Group")

 

 

Result of Annual General Meeting held on 20 August 2020

 

 

Cambridge, UK - 20 August 2020: Nuformix plc (LSE:NFX) announces that all resolutions proposed at its Annual General Meeting held today were duly passed on a poll, the results of which are set out below:

 

 

Votes For

% of Votes Cast

Votes Against

% of Votes Cast

Votes Withheld1

1

To receive the annual report and accounts for the year ended 31 March 2020

160,439,143

97.06

4,859,946

2.94

3,215,648

2

To approve the remuneration report contained within the Annual Report for the year ended 31 March 2020

160,409,517

97.05

4,871,780

2.95

3,233,440

3

To re-appoint Jo Holland as a director

160,421,351

97.06

4,859,946

2.94

3,233,440

4

To re-appoint Christopher Blackwell as a director

139,069,040

82.53

29,447,905

17.47

17,792

5

To appoint Karl Keegan as a director

139,057,206

82.52

29,459,739

17.48

17,792

6

To re-appoint Haysmacintyre as auditor of the Company

160,439,143

97.06

4,859,946

2.94

3,215,648

7

To authorise the directors to determine the remuneration of the auditor

160,421,351

97.05

4,877,738

2.95

3,215,648

8

To authorise the directors to allot shares

139,069,040

84.13

26,230,049

15.87

3,215,648

9

Authority to disapply pre-emption without restriction as to use (Special Resolution)

139,069,040

84.13

26,230,049

15.87

3,215,648

10

Authority to disapply pre-emption for acquisitions or specified capital investments (Special Resolution)

148,518,064

84.99

26,230,049

15.01

3,215,648

11

To authorise the Company to purchase its own shares (Special Resolution)

169,876,333

97.21

4,871,780

2.79

3,215,648

12

To authorise the Company to call a general meeting on not less than 14 clear days' notice (Special Resolution)

148,506,230

84.98

26,241,883

15.02

3,215,648

 

 

1 A vote withheld is not a vote under English law and is therefore not included in the calculation of votes for and against a resolution.

In accordance with Listing Rule 9.6.2, a copy of all resolutions passed as special business will shortly be available for inspection at the National Storage Mechanism document viewing facility at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

 

 

Enquiries:

 

Nuformix plc

Roger Jones, Company Secretary

Fleur Wood, Investor Relations

Email: fleur.wood@nuformix.com

 

 

+44 (0)1223 627222

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RAGBBLFLBVLXBBF
Date   Source Headline
28th May 20267:00 amRNSHalf Year Report
31st Mar 20267:00 amRNSTotal Voting Rights
11th Mar 20267:00 amRNS£1.0 million Placing
10th Mar 20267:00 amRNSConfirmation of US ODD for NXP002 in IPF
3rd Mar 202610:05 amRNSResult of AGM
5th Feb 202612:00 pmRNSPosting of Annual Report and Notice of AGM
27th Jan 20267:00 amRNSAnnual Results for period ended 30 September 2025
28th Nov 20253:22 pmRNSTotal Voting Rights
12th Nov 20257:01 amRNSUpdate re. US FDA ODD Application
12th Nov 20257:00 amRNSResults of Underwritten Open Offer
28th Oct 20257:00 amRNSUnderwritten Open Offer
10th Oct 20257:00 amRNSChange of Auditor
25th Sep 20257:00 amRNS-REuropean Respiratory Society Congress Attendance
11th Aug 20257:00 amRNSUS FDA ODD Application Submitted for NXP002
30th May 20252:24 pmRNSTotal Voting Rights
29th May 20257:00 amRNSConfirmation of European ODD for NXP002
23rd May 20251:08 pmRNSPublication of a Prospectus
22nd May 20257:00 amRNS£210,000 Placing
19th May 20257:00 amRNS-RAttendance at American Thoracic Society Congress
2nd May 20257:00 amRNSHalf-year Report
30th Apr 20257:00 amRNSConfirmation of European Orphan Drug Designation
29th Apr 20257:00 amRNSChange of Registered Office and Company Secretary
14th Apr 20257:00 amRNSExercise of Warrants
9th Apr 20257:00 amRNSNXP002 Update
20th Mar 202511:10 amRNSResult of AGM
28th Feb 202512:30 pmRNSTotal Voting Rights
14th Feb 20252:18 pmRNSPosting of Annual Report and Notice of AGM
30th Jan 20257:00 amRNS£168,750 Placing
29th Jan 20257:00 amRNSAnnual Results for period ended 30 September 2024
28th Jan 20257:00 amRNSNXP002 ODD Application Submitted
13th Jan 20257:00 amRNSNXP002 Orphan Drug Designation Draft Application
29th Nov 20245:00 pmRNSTotal Voting Rights
5th Nov 20242:25 pmRNSDirector/PDMR Dealings
4th Nov 202410:17 amRNSResult of General Meeting
16th Oct 20241:37 pmRNSPublication of Prospectus & Notice of GM
20th Sep 20242:24 pmRNS£300,000 Fundraise
18th Jun 20247:00 amRNSHalf-year Report
17th Jun 20247:00 amRNSPatent Update
19th Mar 20242:39 pmRNSResult of AGM
1st Mar 20247:00 amRNSSubscription to raise £150,000
15th Jan 202411:30 amRNSPosting of Annual Report and Notice of AGM
3rd Jan 20247:00 amRNSResults for the period ended 30 September 2023
18th Dec 20237:00 amRNSNXP001 Update
23rd Oct 20237:00 amRNSNotice of Allowance of NXP002 Patent in Japan
18th Sep 20237:00 amRNSNXP001 Update
24th Aug 20231:22 pmRNSResult of Annual General Meeting
31st Jul 20232:00 pmRNSNotice of AGM
26th Jul 20232:55 pmRNSHolding(s) in Company
2nd Jun 20237:00 amRNSInvestor Online Q&A
25th May 20237:00 amRNSChange of Auditor

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.